Elicio Therapeutics

Company snapshot

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer vaccine space to develop effective, off-the-shelf vaccines. Elicio’s Amphiphile technology aims to

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Elicio Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Elicio Therapeutics.

1. May 23, 2026 Clinical update

   ELI-002 7P — Phase 2

2. May 23, 2026 Clinical update

   ELI-002 2P — Phase 1

3. Jul 29, 2025 Patent grant

   ALK polypeptides and methods of use thereof

4. Mar 11, 2025 Patent grant

   CpG amphiphiles and uses thereof

5. Nov 12, 2024 Patent grant

   Compounds including a mutant KRAS sequence and a lipid and uses thereof

View all clinical trial activity →

• What is Elicio Therapeutics?

  Elicio Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker ELTX. Primary therapeutic focus areas include Minimal Residual Disease, Pancreatic Ductal Adenocarcinoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 4

• Is Elicio Therapeutics publicly traded?

  Yes. Elicio Therapeutics is listed with ticker ELTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Elicio Therapeutics develop or market?

  No drug profiles are currently linked to Elicio Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Elicio Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Elicio Therapeutics focus on?

  Elicio Therapeutics focuses on Minimal Residual Disease, Pancreatic Ductal Adenocarcinoma based on our analysis of their pipeline programs and drug development activities.